Zoetis (ZTS) Competitors

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Zoetis presently has a consensus price target of $141.25, suggesting a potential upside of 84.35%. Royalty Pharma has a consensus price target of $53.71, suggesting a potential upside of 4.00%. Given Zoetis' higher possible upside, equities analysts plainly believe Zoetis is more favorable than Royalty Pharma.

In the previous week, Zoetis had 21 more articles in the media than Royalty Pharma. MarketBeat recorded 49 mentions for Zoetis and 28 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.71 beat Zoetis' score of 0.36 indicating that Royalty Pharma is being referred to more favorably in the news media.

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.8%. Zoetis pays out 35.2% of its earnings in the form of a dividend. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years and Royalty Pharma has raised its dividend for 5 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Zoetis has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Jazz Pharmaceuticals currently has a consensus price target of $230.56, suggesting a potential upside of 3.11%. Zoetis has a consensus price target of $141.25, suggesting a potential upside of 84.35%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

In the previous week, Zoetis had 21 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 49 mentions for Zoetis and 28 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.63 beat Zoetis' score of 0.36 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Jazz Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.14%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Corcept Therapeutics currently has a consensus target price of $74.67, suggesting a potential upside of 45.83%. Zoetis has a consensus target price of $141.25, suggesting a potential upside of 84.35%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

In the previous week, Zoetis had 21 more articles in the media than Corcept Therapeutics. MarketBeat recorded 49 mentions for Zoetis and 28 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.00 beat Zoetis' score of 0.36 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Corcept Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Zoetis has a net margin of 27.80% compared to Supernus Pharmaceuticals' net margin of -3.74%. Zoetis' return on equity of 66.85% beat Supernus Pharmaceuticals' return on equity.

In the previous week, Zoetis had 34 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 49 mentions for Zoetis and 15 mentions for Supernus Pharmaceuticals. Zoetis' average media sentiment score of 0.36 beat Supernus Pharmaceuticals' score of 0.30 indicating that Zoetis is being referred to more favorably in the media.

Zoetis has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Zoetis has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

92.8% of Zoetis shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zoetis currently has a consensus target price of $141.25, indicating a potential upside of 84.35%. Supernus Pharmaceuticals has a consensus target price of $62.17, indicating a potential upside of 25.92%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Supernus Pharmaceuticals.